Patient number			Date of vi



BPH FORM F06.1 December, 1998 Page 1 of 3

FORM NUMBER = (FORM) FORM VERSION = (VERS)

NIH - BPH TRIAL

TITRATION VISIT INVENTORY

This forms should be assembled at Full Must Const. F. 1944	l. A of one dituntion of the						
This form should be completed at End-Week 3 and End-Week 4 of any titration period.							
Part I / IDENTIFICATION							
A. Patient Identification							
1. Patient number (PATID)	clinic patient						
2. Patient's initials (INITS)	first last						
3. Patient's date of birth (DOB)	month day year						
B. <u>Visit Information</u>	month day year						
1. Date of visit (KVSTDT)	month day year						
2. Week of visit (KVIWK)							
Part II / VITAL SIGNS							
C. Blood Pressure Readings							
1. Supine Blood Pressure (After lying 5 minutes)							
a. Blood Pressure Reading (KBPLS)/(KBPLD)	mmHg						
b. Heart Rate (KBPLHR)							
2. Standing Blood Pressure (Immediately)	bpm						
a. Blood Pressure Reading 1 (KBPSS1)/(KBPSD1)	mmHg						
b. Heart Rate 1 (KBPSHR1)	bpm						
Wait 2 minutes							
c. Blood Pressure Reading 2 (KBPSS2)/(KBPSD2)	mmHg						
d. Heart Rate 2 (KBPSHR2)	bpm						
D. Orthostatic Hypotension	YES NO						
Did the patient have orthostatic hypotension? (KORTHYP)							
Orthostatic hypotension is defined as a decrease of more than 20mmHg in supine to standing systolic blood pressure or a decrease of more than 10mmHg in supine to standing diastolic blood							
by otono biood proggard or a accrease or more triall Politilli	19 III Supinio lo standing diastono bioda						

pressure (in either standing blood pressure reading) or the development of significant postural hypotension.

Part III / MEDICATION DISPENSING AND COMPLIANCE AND ADVERSE EVENTS								
E. Number of days since last visit (KCDAYS)								
F. <u>Doxazosin Compliance</u>								
If doxazosin was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section G. 1 mg 2 mg 4 mg 8 mg								
1. Dose of doxazosin (KCDDOSE)								
2. Number of doxazosin tablets dispensed at the last visit (KCDDISL)								
Number of doxazosin tablets returned today (KCDRET)								
4. Compliance (KCDCOMP) tabs dispensed (#2) - tabs returned (#3) days since last visit (question E) X 100 %								
NOTE: Counsel patient if less than 80% compliant with doxazosin.								
5. Number of doxazosin tablets dispensed today (KCDDIST)								
Number of doxazosin tablets dispensed today (KCDDIST) G. Finasteride Compliance								
G. <u>Finasteride Compliance</u> If finasteride was dispensed at the last visit, returned and/or dispensed today, CONTINUE.								
G. <u>Finasteride Compliance</u> If finasteride was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section H.								
G. Finasteride Compliance If finasteride was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section H. 1. Number of finasteride tablets dispensed at the last visit (KCFDISL)								
G. Finasteride Compliance If finasteride was dispensed at the last visit, returned and/or dispensed today, CONTINUE. If not, SKIP to Section H. 1. Number of finasteride tablets dispensed at the last visit (KCFDISL) 2. Number of finasteride tablets returned today (KCFRET) 3. Compliance (KCFCOMP) tabs dispensed (#1) - tabs returned (#2) V 100								

Date of visit

month

day

year

Patient number

BPH FORM F06.1 December, 1998

Page 2 of 3

Patient number		Da	ate of visit mor	nth day yea	ar	BPH FORM F06.1 December, 1998 Page 3 of 3
H. Concomitant Med	<u>lications</u>			YES	NO	
Is the patient curre	ntly taking coded dox	azosin?	(KCDCODE)	1	2	
2. Is the patient curre	ntly taking coded fina	steride?	(KCFCODE)	1	2	
Is the patient cur coded medications		dication	other than the	1	2	
If YES, list below	<i>i</i> :					
a. (KCMCONA)	(KCMCODA)	f.	(KCMCONF)	(KCMCODF)	i	
b. (KCMCONB)	(KCMCODB)	g.	(KCMCONG)	(KCMCODG)	ı	
c. (KCMCONC)	(KCMCODC)	h.	(KCMCONH)	(KCMCODH)	Ī	
d. (KCMCOND)	(KCMCODD)	i.	(KCMCONI)	(KCMCODI)		
e. (KCMCONE)	(KCMCODE)	j.	(KCMCONJ)	(KCMCODJ)		
any adverse exp abnormal labora	cheduled follow-up vinceriences, drug reaction tory values, hospitaliner complications or partical to the complications or partical to the complications of the complete the comple	ions, sid izations,	le effects, , coded	YES 1	NO 2	
If YES, an Adverse Ev	rent Report (Form E0	5) MUS	T be completed			